Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sIPV-sIPV-bOPV vaccination schedule
- Development stage
- Phase 4
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
The sIPV-sIPV-bOPV vaccination schedule is a sequential '2+1' immunization regimen developed for the prevention of poliomyelitis. This regimen consists of two initial doses of Sinovac's Sabin-strain inactivated poliovirus vaccine (sIPV) followed by a third dose of bivalent oral poliovirus vaccine (bOPV). The sIPV component is a biologic containing inactivated poliovirus types 1, 2, and 3 produced in Vero cells, while the bOPV component contains live-attenuated poliovirus types 1 and 3. This schedule is designed to provide robust immunity against all three poliovirus serotypes while mitigating the risk of vaccine-associated paralytic poliomyelitis (VAPP) that can occur with all-OPV schedules. Clinical trials have demonstrated high seroconversion rates (100% for types 1 and 3, and 95% for type 2) and a favorable safety profile. This regimen was implemented in China's routine immunization program starting in 2016 to address global IPV supply shortages and support the global polio eradication initiative.
- Other names
- 2+1 sequential immunization schedulesIPV-sIPV-bOPV sequential schedule
02
Targets
Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)
Beyond the preview
Go deeper on sIPV-sIPV-bOPV vaccination schedule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sIPV-sIPV-bOPV vaccination schedule.